Autopsy report · NCT02466243

Safety, Tolerability, and Efficacy of JBT-101 in Subjects With Dermatomyositis

“Sponsor terminated open-label extension.”

The sponsor’s own words in the registry.

Life of this trial

• Ran for about 5 years 7 months before it stopped.
• 22 participants enrolled.
• Results were posted on the registry 2 years after it ended.

Vital statistics

Status

Terminated

Phase

Phase 2

Sponsor

Corbus Pharmaceuticals Inc.

Sponsor type

Industry

Conditions

Dermatomyositis

Interventions

JBT-101; Placebo

Participants

22

Sites

1

Countries

United States

Trials that died the same way

• A Study to Assess the Long-term Safety and Efficacy of a Subcutaneous Formulation of Efgartigimod PH20 SC in Adults With Pemphigus (Vulgaris or Foliaceus)
  “Based on the lack of observed efficacy in the primary study ARGX-113-1904, the sponsor decided to discontinue the open-label extension study.” (72% match in meaning)
• RibFix Advantage™ Post-Market Follow-Up
  “Sponsor Terminated” (67% match in meaning)
• Estradiol Therapy In Transgender Women to Research Interactions With HIV Therapy
  “Trial terminated by Sponsor.” (67% match in meaning)
• Ponatinib in Advanced or Metastatic Medullary Thyroid Cancer
  “Closed by sponsor” (66% match in meaning)
• Magnetic Muscle Stimulation of Abdominal Muscle
  “Sponsor Discontinued due to business decision.” (66% match in meaning)

Look deeper

• The official registry record (the source of truth)
• Record history: every change the sponsor made
• Open it in the database

Everything here comes from the current ClinicalTrials.gov record. The timeline uses the record’s dates; dates marked planned are the sponsor’s plans. The cause of death is an automatic, unverified label. This is research information, not medical advice.